Mr. Dwight Gorham reports

INTELGENX PROVIDES UPDATE ON RESEARCH COLLABORATION EVALUATING MONTELUKAST VERSAFILM(TM) FOR THE TREATMENT OF PARKINSON'S DISEASE

IntelGenx Corp. has executed a research grant agreement with Karolinska University Hospital. The manufacturing of both active and placebo films is under way in preparation for a planned multicentre, randomized, double-blind, placebo-controlled clinical study to investigate the use of IntelGenx's Montelukast VersaFilm for the treatment of Parkinson's disease (PD).

The study will be conducted at the Karolinska University Hospital under IntelGenx's previously announced research collaboration with Prof. Per Svenningsson, MD, PhD, who will serve as the study's principal investigator. Prof. Svenningsson -- a professor of clinical neuroscience who investigates the pathogenic mechanisms of PD -- previously conducted a clinical study utilizing the tablet form of Montelukast for the treatment of PD, where two tablets of 10-milligram Montelukast were administered twice daily, for a total daily dose of 40 mg.

"Prof. Svenningsson's interest in evaluating Montelukast VersaFilm for the treatment of PD reflects his confidence in the drug's therapeutic potential, which is based on findings from his earlier Montelukast tablet study, the higher bioavailability of our film formulation as well as the need for a more convenient dosing method," said Dwight Gorham, IntelGenx's chief executive officer. "As the planned study will assess Montelukast in doses exceeding 40 mg, Montelukast VersaFilm offers study participants an attractive dosing alternative to tablets, which would require administration of multiple tablets several times per day."

Prof. Svenningsson will sponsor the study through a grant of 20 million Swedish kronor (approximately $2-million (U.S.)) awarded by the Swedish Research Council, Sweden's largest governmental research funding body. Upon completion of the study, IntelGenx will have the option to acquire the developed intellectual property rights and study data for a predetermined low five-digit amount and use the findings to further develop its Montelukast VersaFilm program for PD treatment.

About IntelGenx Corp.

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next-generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development, analytical method development, clinical monitoring, IP, and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

We seek Safe Harbor.